The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.
Investigators report that lifestyle interventions during pregnancy reduce gestational diabetes risk, with effects varying by diagnostic criteria and maternal education level.
Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.
The 2025 US Department of Veterans Affairs and US Department of Defense asthma guideline introduces 21 evidence-based recommendations for primary care, redefining stepwise treatment, comorbidity management, and reliever strategy.